# Osteogenesis Imperfecta FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/osteogenesis-imperfecta

> 6 upcoming FDA catalysts in osteogenesis Imperfecta: setrusumab (RARE) on January 2027 (primary completion); setrusumab (RARE) on Jan to Apr 2027 (topline data readout); romosozumab (AMGN) on May to Aug 2027 (topline data readout); romosozumab (AMGN) on May 2027 (primary completion); and 2 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| October 20, 2025 | [Setrusumab primary completion](https://sec-api.dev/pdufa/setrusumab) | RARE | Osteogenesis Imperfecta | completed | "NCT05125809 (Setrusumab vs Placebo for Osteogenesis Imperfecta): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2025-10-20 (ACTUAL); Lead Sponsor Ultragenyx Pharmaceutical Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05125809)) |
| October 23, 2025 | [Bisphosphonate primary completion](https://sec-api.dev/pdufa/bisphosphonate) | RARE | Osteogenesis Imperfecta | completed | "NCT05768854 (Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-23 (ACTUAL); Lead Sponsor Ultragenyx Pharmaceutical Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05768854)) |
| January 2027 | [Setrusumab primary completion](https://sec-api.dev/pdufa/setrusumab) | RARE | Osteogenesis Imperfecta | scheduled | "NCT06636071 (Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01 (ESTIMATED); Lead Sponsor Ultragenyx Pharmaceutical Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06636071)) |
| Jan to Apr 2027 | [Setrusumab topline data readout](https://sec-api.dev/pdufa/setrusumab) | RARE | Osteogenesis Imperfecta | scheduled | "NCT06636071 (Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01 (ESTIMATED); Lead Sponsor Ultragenyx Pharmaceutical Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06636071)) |
| May to Aug 2027 | [Romosozumab topline data readout](https://sec-api.dev/pdufa/romosozumab) | AMGN | Osteogenesis Imperfecta | scheduled | "NCT05972551 (Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-04 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05972551)) |
| May 2027 | [Romosozumab primary completion](https://sec-api.dev/pdufa/romosozumab) | AMGN | Osteogenesis Imperfecta | scheduled | "NCT05972551 (Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-04 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05972551)) |
| Apr to Jul 2028 | [AMGEN INC topline data readout](https://sec-api.dev/companies/amgn/catalysts) | AMGN | Osteogenesis Imperfecta | scheduled | "NCT07366086 (Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-19 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07366086)) |
| April 2028 | [AMGEN INC primary completion](https://sec-api.dev/companies/amgn/catalysts) | AMGN | Osteogenesis Imperfecta | scheduled | "NCT07366086 (Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-19 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07366086)) |

## Drugs

- [Setrusumab](https://sec-api.dev/pdufa/setrusumab) (RARE)
- [Bisphosphonate](https://sec-api.dev/pdufa/bisphosphonate) (RARE)
- [Romosozumab](https://sec-api.dev/pdufa/romosozumab) (AMGN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/osteogenesis-imperfecta.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Osteogenesis Imperfecta FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/osteogenesis-imperfecta

```bibtex
@misc{secapidev_indications_osteogenesis_imperfecta_20261116,
  title        = {Osteogenesis Imperfecta FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/osteogenesis-imperfecta}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_osteogenesis_imperfecta_20261116","title":"Osteogenesis Imperfecta FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/osteogenesis-imperfecta","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
